You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The real-time RT-PCR multiplex test is intended for the simultaneous detection and differentiation of SARS-CoV-2, influenza A virus, and influenza B virus.
The deal will join Tangen's GeneSpark point-of-care instrument with LabWare's portable disease surveillance kit for SARS-CoV-2.
The firm's influenza testing revenue reached record highs in January and February, and continued at a high level throughout the end of the quarter.
The platform can detect a single virus in more than 1,000 samples at a time or more than 160 viruses, including SARS-CoV-2, in a small number of samples.
Technology partners on the study include BioMérieux and SkylineDx, as well as Imperial College London's biomedical electronics unit.
The researchers are studying use of pharmacy testing to monitor hypertension and cholesterol as well as for detecting and managing various infectious diseases.
A recent study established high sensitivity and specificity for three CLIA waived point-of-care molecular flu tests in pediatric samples.
The firm is developing the test under a contract with the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority.
The firm saw a 36 percent increase in influenza product sales compared to the third quarter last year.
Cambridge, UK-based Sense Biodetection will use the funding to develop a portfolio of instrument-free, point-of-care molecular diagnostic tests.